New seven-year findings from CooperVision’s MiSight 1 day contact lens clinical trial shows no evidence of myopia control rebound in children 12 months after treatment has ended.
The study is the world’s longest continuous running soft contact lens clinical trial for myopia control.
CooperVision previously reported that MiSight 1 day showed sustained slowing of myopia progression across multiple years of treatment. This was observed in a cohort that wore MiSight 1 day for the study’s first six years as well as the original control group who were switched into MiSight 1 day for three years.
Mr Paul Chamberlain, the study’s principal investigator and CooperVision director of research programs, said the latest study results should give eyecare professionals even more confidence in prescribing MiSight 1 day.
“Our unparalleled research clearly illustrates the tremendous potential of MiSight 1 day for children of different ages and with different levels of myopia, regardless of when they start treatment,” he said.
The latest data illustrates that MiSight 1 day offers a highly-desired proportional myopia control treatment effect. Abnormal axial length growth slowed by an average of approximately 50% with all tested ages (8-17 years).
Because younger children’s myopia progresses faster than in older children, introducing MiSight 1 day at the earliest opportunity may offer the maximum cumulative benefit over time, the company said.
In the study’s seventh year, participants were transitioned from MiSight 1 day to a single vision contact lens to evaluate if treatment gains would be retained. Myopic progression then occurred only at anticipated ‘age-normal’ levels – not at an accelerated “catch up” rate that would offset prior myopia control gains – thereby indicating no rebound effect.
Study investigator Dr Nicola Logan, Professor of Optometry and Physiological Optics at Aston University, said the investigating team saw these children grow into young adults during their seven years in the study.
“It is personally as well as professionally fulfilling to know that the benefits of treatment are retained. As MiSight 1 day becomes more widely available and as myopia management becomes the standard of care, I hope other eyecare professionals will experience that same joy,” she said.
MiSight 1 day contact lenses are specifically designed for myopia control and are FDA approved to slow the progression of myopia in children aged 8-12 at the initiation of treatment.
In August, MiSight 1 day received approval from the Chinese National Medical Products Administration to become the first indicated product of any type that may slow the progression of axial length.
CooperVision researchers shared their findings at the American Academy of Optometry Annual Meeting Boston in November.
More reading